Issue Date: November 20, 2017 | Web Date: November 14, 2017
Bayer, Loxo to jointly develop TRK inhibitors
In a deal worth up to $1.5 billion, Bayer and Loxo Oncology will jointly develop two Loxo drug candidates, larotrectinib and LOXO-195, for treating cancers caused by a rare genetic mutation. Loxo gets $400 million upfront; the remainder of the money is tied to the approval and sale of the two compounds.
Larotrectinib and the follow-on compound LOXO-195 both block TRK gene fusions, a chromosomal mismatch found in less than . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society